Blog
Qizheng Tibetan Medicine’s revenue grew by 15.62% in 2019, and it also released its eleventh Social Responsibility Report.
Release time:
2020-04-30 16:55
On the 29th, Qizheng Tibetan Medicine disclosed its annual report. In 2019, the company achieved operating revenue of 14,026.769 million yuan, an increase of 15.62% over the same period last year. Its operating profit reached 4,015.286 million yuan, up 13.41% from the previous year.
According to the annual report, Qizheng Tibetan Medicine has a total of 55 Tibetan medicine products—centered around 12 exclusive varieties or exclusive dosage forms such as Xiaotong Paste and Baimai Ointment—as well as 72 approved drug registration numbers. Among these, 9 are over-the-counter (OTC) products and 2 are classified as national technical secrets (secret level). As of the end of 2019, the company’s flagship product, Xiaotong Paste, had been included in the National Essential Medicines List; 17 products were listed in the “National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2019 Edition);” 35 products were included in local provincial medical insurance catalogs; 49 products were included in local essential medicine lists; 9 products were included in local low-price drug lists; and 2 products were included in the National Emergency (Rescue) Drug List.
In 2019, the company achieved dual growth in both the medical and retail markets by further deepening its academic marketing and brand marketing efforts and intensifying its channel penetration. While its core products experienced comprehensive growth, new products also delivered strong sales performance, contributing to the company’s overall business growth. The company launched the construction of the Qizheng Internet-based Greater Health Platform, completing the establishment of an integrated e-commerce front-to-back-end organizational structure that encompasses operations, promotion, customer service, and product management. The company has successfully opened and is now operating flagship stores including the Qizheng Pharmaceutical Flagship Store (Alibaba Health Pharmacy), the Qizheng Official Flagship Store (JD Pharmacy), and the Qizheng Pharmaceutical & Health Flagship Store (Pinduoduo), thus ushering in a new era of “Internet Plus” for the company.
The company also released the “Qizheng Tibetan Medicine 2019 Social Responsibility Report.” This marks the eleventh consecutive year that Qizheng Tibetan Medicine has published a social responsibility report. In the report, Chairwoman Lei Jufang stated that during the COVID-19 pandemic response, the value of traditional Chinese medicine—including ethnic medicines—has become particularly evident. Several products manufactured and owned by the company, including Influenza Pills, Lung-Clearing and Cough-Relieving Pills, Twelve-Flavor Yishoucao (Powder), Dasima Bao Pills, Renqing Mangjue Capsules, and Cuithang Granules, have successively been included in the lists of recommended medications for epidemic prevention and control in the three provinces and autonomous regions of Tibet, Qinghai, and Gansu.
Reporting media: Shanghai Securities Journal·China Securities Network
Report link: http://ggjd.cnstock.com/company/scp_ggjd/tjd_bbdj/202004/4527983.htm
Recommended News
2026-05-25
Copyright Qizheng Tibetan Medicine Co., Ltd. All rights reserved. ICP Filing Number:
Internet drug information service qualification certificate number:（藏） Non-Commercial - 2018-0004 SEO